Ionis Pharmaceuticals, Inc. (IONS)
| Market Cap | 13.23B |
| Revenue (ttm) | 966.96M |
| Net Income (ttm) | -256.34M |
| Shares Out | 161.97M |
| EPS (ttm) | -1.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,714,985 |
| Open | 82.19 |
| Previous Close | 81.81 |
| Day's Range | 80.64 - 82.44 |
| 52-Week Range | 23.95 - 83.61 |
| Beta | 0.30 |
| Analysts | Strong Buy |
| Price Target | 80.71 (-1.19%) |
| Earnings Date | Oct 29, 2025 |
About IONS
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSE... [Read more]
Financial Performance
In 2024, Ionis Pharmaceuticals's revenue was $705.14 million, a decrease of -10.48% compared to the previous year's $787.65 million. Losses were -$453.90 million, 23.9% more than in 2023.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for IONS stock is "Strong Buy." The 12-month stock price target is $80.71, which is a decrease of -1.19% from the latest price.
News
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to zilganers...
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olezarsen...
Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies London Healthcare Conference 2025 Transcript
Ionis Pharmaceuticals, Inc. ( IONS) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants A...
Biogen Completes Acquisition of Alcyone Therapeutics
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CN...
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee for Medicinal Products for Human Use (CHMP...
Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2025 Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. ( IONS) Stifel 2025 Healthcare Conference November 13, 2025 8:00 AM EST Company Participants Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Elizabeth L....
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $700.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030 (the “...
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Stifel 2025 Heal...
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $700.0 million aggregate princip...
Ionis Pharmaceuticals, Inc. (IONS) Discusses Detailed Phase III Results for Olezarsen in Severe Hypertriglyceridemia Transcript
Ionis Pharmaceuticals, Inc. ( IONS) Discusses Detailed Phase III Results for Olezarsen in Severe Hypertriglyceridemia November 8, 2025 3:00 PM EST Company Participants D. Walke - Senior Vice Presiden...
Ionis: Near-Term Launches With Blockbuster Potential Boosts Upside Despite Stock Rally
Ionis Pharmaceuticals maintains a Buy rating as its transformation to a commercial company accelerates, driven by wholly-owned product launches and revenue growth. Q3 results highlight a revenue shift...
Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Sunday shared results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG), a condition characterized by dan...
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypert...
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA™ (donidalorsen), the first and only RNA-targeted prophylactic medicine for...
Ionis: What Upside Is Left After Shares Rocketed Higher Following Positive Trial Data?
Ionis Pharmaceuticals, Inc. has surged on strong phase-3 trial data and a robust pipeline, but much optimism is already priced in. IONS boasts recent drug launches (Wainua, Tryngolza, Dawnzera) with s...
Ionis Pharmaceuticals, Inc. (IONS) Q3 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. ( IONS) Q3 2025 Earnings Call October 29, 2025 11:30 AM EDT Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Direct...
Ionis reports third quarter 2025 financial results and highlights progress on key programs
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2025. ...
Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that detailed data from the landmark pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with se...
Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the company was named as a top employer to work for by Science magazine in its annual Top Employer survey ...
Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., Ionis' chief executive officer, was awarded the 2025 Lifetime Achievement Awar...
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares
On October 17, 2025, Capricorn Fund Managers Ltd disclosed a new stake in Ionis Pharmaceuticals, acquiring approximately 162,800 shares in a trade estimated at $10.65 million based on average quarterl...
Ionis to hold third quarter 2025 financial results webcast
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, October 29th at 11:30 a.m. Eastern Time to discuss its thir...
Ionis Pharmaceuticals, Inc. (IONS) Shareholder/Analyst Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shareholder/Analyst Call October 7, 2025 8:30 AM EDT Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO &...
Ionis Pharmaceuticals CEO Brett Monia on the drugs they are focused on
Ionis Pharmaceuticals CEO Brett Monia joins CNBC's 'Squawk Box' to discuss RNA-targeted therapeutics, the drugs the company is focusing on, and more
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today is hosting its 2025 Innovation Day in New York City. Ionis leaders will highlight the company's recent and near-term...